




NewLink Genetics Corporation  
Investor Relations Department  
2503 South Loop Drive  
Ames, IA 50010  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

## Company Profile

---

Founded in 1999, NewLink Genetics is an immuno-oncology company focused on discovering and developing novel products for the treatment of cancer. The drug discovery and development teams at NewLink Genetics are relentlessly pursuing a wide range of immuno-oncology portfolio candidates with the potential to change the oncology landscape. NewLink Genetics' portfolio includes two small-molecule product candidates currently in clinical development. These product candidates inhibit the IDO pathway, a key immuno-oncology target, and focus on breaking the immune system's tolerance to cancer.

## Press Releases [\[ View all \]](#)

---

*Jun 8, 2017*

[NewLink Genetics to Regain Rights to GDC-0919](#)

*Jun 5, 2017*

[NewLink Genetics' Indoximod + PROVENGE® Results in Statistically Significant Improvement in Radiographic Progression-Free Survival \(rPFS\) for Patients with Metastatic Castration Resistant Prostate Cancer \(mCRPC\) in Phase 2 Trial](#)

*Jun 2, 2017*

[Results from Clinical Trial of Indoximod Plus Chemotherapy for Patients with Metastatic Breast Cancer](#)

*May 18, 2017*

[Data from Clinical Study of NewLink Genetics' IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association Congress](#)

*May 17, 2017*

[Data from Clinical Studies of NewLink Genetics' Two Distinct IDO Pathway Inhibitors to Be Presented at ASCO 2017](#)

## Financials [\[ View all \]](#)

---

[First Quarter Financial Results](#)

*Mar 6, 2017*

[Annual Report \(10-K\)](#)

*Mar 31, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 5, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 8, 2016*

[Quarterly Report \(10-Q\)](#)

*Aug 5, 2016*

[Quarterly Report \(10-Q\)](#)